• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16861 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     NIHR Health Technology Assessment programme Laparoscopic hysterectomy versus open abdominal hysterectomy for women with a benign gynaecological condition: the LAVA RCT
2026     NIHR Health Services and Delivery Research programme Developing research resources and minimum data set for care homes’ adoption and use (DACHA)
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of improving sleep via carer delivered strategies in people with dementia: the DREAMS START parallel multi-centre RCT
2026     NIHR Health Technology Assessment programme The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis
2026     NIHR Health Technology Assessment programme Conservative versus liberal oxygenation targets in critically ill children: the Oxy-PICU RCT
2026     NIHR Health Technology Assessment programme Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a randomised placebo-controlled trial
2026     NIHR Health Technology Assessment programme Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial)
2026     NIHR Health Technology Assessment programme Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessment
2026     NIHR Health Technology Assessment programme Gabapentin as an adjunct to multimodal pain regimens in surgical patients: the GAP placebo-controlled RCT and economic evaluation
2026     NIHR Health Technology Assessment programme Establishing the safety of waterbirth for mothers and their babies: the POOL cohort study with nested qualitative component
2026     NIHR Health Technology Assessment programme A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis
2026     Washington Singer Press test record #3
2026     NIHR Health Technology Assessment programme Roux-en-Y gastric bypass, adjustable gastric banding or sleeve gastrectomy for severe obesity: the By-Band-Sleeve randomised controlled trial
2026     NIHR Health Technology Assessment programme Digitally enabled therapy for chronic tic disorders and Tourette Syndrome: a systematic review and economic evaluation
2026     NIHR Health Technology Assessment programme The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
2026     National Institute for Health and Care Excellence (NICE) Balloon cryoablation for Barrett's oesophagus. NICE HealthTech guidance 767
2026     National Institute for Health and Care Excellence (NICE) Digital self-help for eating disorders: early value assessment. NICE HealthTech guidance 768
2026     National Institute for Health and Care Excellence (NICE) Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment. NICE HealthTech guidance 766
2026     National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1119
2026     National Institute for Health and Care Excellence (NICE) Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1118
2026     National Institute for Health and Care Excellence (NICE) Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 1120
2026     National Institute for Health and Care Excellence (NICE) Acoramidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1121
2026     National Institute for Health and Care Excellence (NICE) Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1122
2026     National Institute for Health and Care Excellence (NICE) Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal). NICE technology appraisal guidance 1123
2026     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal). NICE technology appraisal guidance 1125
2026     National Institute for Health and Care Excellence (NICE) Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal). NICE technology appraisal guidance 1124
2026     National Institute for Health and Care Excellence (NICE) Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy. NICE technology appraisal guidance 1126
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of medical management versus surgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT
2026     NIHR Health Technology Assessment programme Addition of early vocational advice to usual primary care on sickness absence in employed adults: exploratory findings from the discontinued WAVE Randomised Controlled Trial
2026     NIHR Health Services and Delivery Research programme Referral pathways into the NHS Digital Weight Management Programme for musculoskeletal and perioperative patients: rapid process evaluation
2026     NIHR Health Technology Assessment programme Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review
2026     Washington Singer Press This is a test record for deletion [Limited series no. 522]
2026     Washington Singer Press This is a test record for deletion [Limited series no. 521]
2026     NIHR Health Services and Delivery Research programme Models of perinatal care for women using drugs and their infants: synopsis of The Stepping Stones Study
2026     NIHR Health Technology Assessment programme Home-based extended rehabilitation for older people with frailty (HERO): a multicentre randomised controlled trial with health economic analysis and process evaluation
2026     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD comprehensive synopsis
2026     NIHR Health Technology Assessment programme Timing of birth to improve outcomes in chronic or gestational hypertension: the WILL RCT
2026     NIHR Health Technology Assessment programme Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal
2026     NIHR Health Services and Delivery Research programme A randomised feasibility trial of an intervention involving mental health support workers as link workers to improve dental visiting in people with severe mental illness: The Mouth Matters in Mental Health Study
2026     NIHR Health Technology Assessment programme Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
2026     Health Technology Wales (HTW) Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal cancer
2025     National Institute for Health and Care Excellence (NICE) Slide sheets for moving or repositioning a person: late-stage assessment. NICE HealthTech guidance 745
2025     National Institute for Health and Care Excellence (NICE) Drug-eluting stents for treating coronary artery disease: late-stage assessment. NICE HealthTech guidance 747
2025     National Institute for Health and Care Excellence (NICE) Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment. NICE HealthTech guidance 751
2025     National Institute for Health and Care Excellence (NICE) Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment. NICE HealthTech guidance 753
2025     National Institute for Health and Care Excellence (NICE) One-piece closed bags for colostomies: late-stage assessment. NICE HealthTech guidance 754
2025     National Institute for Health and Care Excellence (NICE) Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment. NICE HealthTech guidance 757
2025     National Institute for Health and Care Excellence (NICE) Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment. NICE HealthTech guidance 759
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment. NICE HealthTech guidance 739
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for orthopaedic procedures: early value assessment. NICE HealthTech guidance 743
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for soft tissue procedures: early value assessment. NICE HealthTech guidance 742
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment. NICE HealthTech guidance 746
2025     National Institute for Health and Care Excellence (NICE) Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment. NICE HealthTech guidance 748
2025     National Institute for Health and Care Excellence (NICE) Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment. NICE HealthTech guidance 756
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment. NICE HealthTech guidance 760
2025     National Institute for Health and Care Excellence (NICE) Digital platforms to support cardiac rehabilitation: early value assessment. NICE HealthTech guidance 761
2025     Scottish Health Technologies Group (SHTG) Esaote® extremity MRI scanners
2025     HTA South [Screening for diabetic retinopathy with artificial intelligence for image analysis: a systematic review and assessment of medical, economical, ethical and organisational aspects]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Guidance for searching and finding public contributions to pharmaceutical R&D
2025     Austrian Institute for Health Technology Assessment (AIHTA) Telecardiology for heart failure patients: Benefit assessment and evaluation concept for telemedicine-supported care programmes in Austria
2025     Austrian Institute for Health Technology Assessment (AIHTA) Nudging interventions to optimise physician prescribing behaviour
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Cervical length screening followed by progesterone with or without additional treatment for short cervix to prevent preterm birth
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Radiofrequency or microwave ablation versus surgery for treatment of benign non-toxic or toxic nodules, and toxic diffuse autoimmune hyperthyroidism (Graves' disease)
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of hospital at home compared with in-hospital care according to current Swedish healthcare routine
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of parenteral clomipramine compared to oral clomipramine or other treatments for depression or obsessive-compulsive disorder
2025     WorkSafeBC Magnesium to treat chronic pain
2025     WorkSafeBC Arthrosamid® in treating knee osteoarthritis (OA)
2025     WorkSafeBC Efficacy / effectiveness of Ubiquinol® in treating chronic fatigue syndromes post acute COVID-19 syndromes
2025     WorkSafeBC Efficacy/effectiveness of Vyvanse® in treating chronic fatigue syndromes (CFS) or post acute COVID-19 syndromes
2025     WorkSafeBC Efficacy and / or effectiveness of SportVis as treatment for subacromial bursitis - 2025 update
2025     WorkSafeBC Platelet rich plasma in treating disc herniation or facet joint pain
2025     WorkSafeBC Cryotherapy in treating meniscal tears
2025     WorkSafeBC Combining IV and oral ketamine to treat chronic non-cancer pain
2025     WorkSafeBC Complex regional pain syndrome (CRPS) diagnostic criteria at time of evaluation and its role on treatment outcomes
2025     WorkSafeBC Red light therapy for Achilles / other tendon rupture
2025     WorkSafeBC Effectiveness of extra corporeal shockwave therapy (ESWT) in treating biceps tendinopathy
2025     WorkSafeBC Firefighting and coronary heart disease
2025     WorkSafeBC CRPS and dental pain/sensitivity
2025     WorkSafeBC Traumatic brain injury (TBI) without any ocular trauma and cataract development
2025     WorkSafeBC Pulsed electromagnetic field therapy (PEMF), hyperbaric chamber, or acupuncture for treatment of hypersensitivity pneumonitis
2025     WorkSafeBC Meniscal injury and time to TKA: partial meniscectomy vs. conservative treatment
2025     WorkSafeBC Industrial instrument mechanic and development of multiple myeloma
2025     WorkSafeBC The effects of Sb2O3 [antimony trioxide] on human health
2025     WorkSafeBC Tower crane operators and low back pain
2025     WorkSafeBC Firefighting and Crohn’s disease
2025     WorkSafeBC Aerolase® System in treating burn/scar tissue
2025     WorkSafeBC IV ketamine therapy for long Covid
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Maternal and perinatal mortality and severe morbidity of midwife assisted births outside hospital compared with hospital births
2025     The Regional Health Technology Assessment Centre (HTA-centrum) Dental assessment for prevention of medication-related osteonecrosis of the jaw in adults with early breast cancer
2025     Austrian Institute for Health Technology Assessment (AIHTA) Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
2025     Austrian Institute for Health Technology Assessment (AIHTA) Social prescribing in primary care. Development of an Austrian programme theory based on realist evidence
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive medical check-ups in Austria. Risk scores for cardiovascular disease: a systematic review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the programme on preventive health check-ups in Austria. Brief interventions for lifestyle counselling: umbrella review and qualitative survey
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for postcardiotomy cardiogenic shock in adults. NICE interventional procedures guidance 810
2025     National Institute for Health and Care Excellence (NICE) Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1114
2025     National Institute for Health and Care Excellence (NICE) Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 1113
2025     National Institute for Health and Care Excellence (NICE) Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1115
2025     National Institute for Health and Care Excellence (NICE) Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1116
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency. NICE technology appraisal guidance 1117